Bayesian Quantitative Disease–Drug–Trial Models for Parkinson’s Disease to Guide Early Drug Development
Journal Title: The AAPS Journal - Year 2011, Vol 13, Issue 4
Abstract
The problem we have faced in drug development is in its efficiency. Almost a half of registration trials are reported to fail mainly because pharmaceutical companies employ one-size-fits-all development strategies. Our own experience at the regulatory agency suggests that failure to utilize prior experience or knowledge from previous trials also accounts for trial failure. Prior knowledge refers to both drug-specific and nonspecific information such as placebo effect and the disease course. The information generated across drug development can be systematically compiled to guide future drug development. Quantitative disease–drug–trial models are mathematical representations of the time course of biomarker and clinical outcomes, placebo effects, a drug’s pharmacologic effects, and trial execution characteristics for both the desired and undesired responses. Applying disease–drug–trial model paradigms to design a future trial has been proposed to overcome current problems in drug development. Parkinson’s disease is a progressive neurodegenerative disorder characterized by bradykinesia, rigidity, tremor, and postural instability. A symptomatic effect of drug treatments as well as natural rate of disease progression determines the rate of disease deterioration. Currently, there is no approved drug which claims disease modification. Regulatory agency has been asked to comment on the trial design and statistical analysis methodology. In this work, we aim to show how disease–drug–trial model paradigm can help in drug development and how prior knowledge from previous studies can be incorporated into a current trial using Parkinson’s disease model as an example. We took full Bayesian methodology which can allow one to translate prior information into probability distribution.
Authors and Affiliations
Joo Yeon Lee, Jogarao V. S. Gobburu
Keywords
Related Articles
- EP ID EP681338
- DOI 10.1208/s12248-011-9293-6
- Views 75
- Downloads 0
Implementing Dried Blood Spot Sampling for Clinical Pharmacokinetic Determinations: Considerations from the IQ Consortium Microsampling Working Group
Rodent animal models are typically employed in these studies. The reduced blood volumes required for DBS can enable serial bleeding and, consequently, elimination of satellite animal groups and reduction of compound use....
Mitochondria-targeted peptide antioxidants: Novel neuroprotective agents
Increasing evidence suggests that mitochondrial dysfunction and oxidative stress play a crucial role in the majority of neurodegenerative diseases. Mitochondria are a major source of intracellular reactive oxygen species...
Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling
Precision medicine promises to improve both the efficacy and safety of therapeutic products by better informing why some patients respond well to a drug, and some experience adverse reactions, while others do not. Pharma...
Monoamine Transporter Structure, Function, Dynamics, and Drug Discovery: A Computational Perspective
The online version of this article (doi:10.1208/s12248-012-9391-0) contains supplementary material, which is available to authorized users.
Neonatal Immune Tolerance Induction to Allow Long-Term Studies With an Immunogenic Therapeutic Monoclonal Antibody in Mice
The purpose of this study is to test the feasibility of neonatal immune tolerance induction in mice to enable long-term pharmacokinetic studies with immunogenic therapeutic monoclonal antibodies (mAb). Neonatal immune to...